Advertisement

Topics

bluebird bio Reports Second Quarter 2017 Financial Results and Recent Operational Progress

11:39 EDT 8 Aug 2017 | Biotech-Finances

Wednesday, August 2nd 2017 at 8:05pm UTC – Completed enrollment in Northstar-2, Phase 3 study of LentiGlobinTM drug product in patients with transfusion-dependent β-thalassemia (TDT) and non-β0/β0 genotypes – – Presented updated clinical results from studies in relapsed/refractory multiple myeloma, TDT and severe sickle cell disease (SCD) at American Society of Clinical Oncology (ASCO) Annual …

Cet article bluebird bio Reports Second Quarter 2017 Financial Results and Recent
Operational Progress
est apparu en premier sur EEI-BIOTECHFINANCES.

Original Article: bluebird bio Reports Second Quarter 2017 Financial Results and Recent Operational Progress

NEXT ARTICLE

More From BioPortfolio on "bluebird bio Reports Second Quarter 2017 Financial Results and Recent Operational Progress"

Quick Search
Advertisement
 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...